Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Accumulated Expenses: 2014-2018

Historic Accumulated Expenses for Viking Therapeutics (VKTX) over the last 3 years, with Mar 2018 value amounting to $34,000.

  • Viking Therapeutics' Accumulated Expenses was N/A to $34,000 in Q1 2018 from the same period last year, while for Mar 2018 it was $34,000, marking a year-over-year change of. This contributed to the annual value of $22,000 for FY2017, which is 36.95% down from last year.
  • As of Q1 2018, Viking Therapeutics' Accumulated Expenses stood at $34,000, which was up 54.55% from $22,000 recorded in Q4 2017.
  • In the past 5 years, Viking Therapeutics' Accumulated Expenses ranged from a high of $183,611 in Q4 2015 and a low of $9,982 during Q3 2017.
  • Over the past 3 years, Viking Therapeutics' median Accumulated Expenses value was $22,674 (recorded in 2016), while the average stood at $27,620.
  • Per our database at Business Quant, Viking Therapeutics' Accumulated Expenses tumbled by 91.37% in 2016 and then spiked by 467.51% in 2017.
  • Over the past 5 years, Viking Therapeutics' Accumulated Expenses (Quarterly) stood at $77,222 in 2014, then surged by 137.77% to $183,611 in 2015, then slumped by 81.00% to $34,894 in 2016, then crashed by 36.95% to $22,000 in 2017, then reached $34,000 in 2018.
  • Its last three reported values are $34,000 in Q1 2018, $22,000 for Q4 2017, and $9,982 during Q3 2017.